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Peritoneal carcinomatosis is a pattern of disease 
spread in gastrointestinal malignancies, ovarian cancers 
and sarcomas. It has always been regarded as a terminal 
condition. Important natural history studies established 
a 3-month median survival and 6-month overal survival in 
this group of patients [1]. Nowadays standard strategy for 
management of peritoneal carcinomatosis includes ag-
gressive surgery combined with hyperthermic intraperi-
toneal chemotherapy [2]. Though the results of treatment 
for the patients are improved, the problem of peritoneal 
carcinomatosis is still unresolved [3, 4].
Photodynamic therapy (PDT) is a modality based on 
cytotoxic effect of radical oxygen species through acti-
vation of the photosensitizer by light of the appropriate 
wavelength at the treatment site. The antitumor effects 
of PDT result from direct tumor cell kill, leading to necro-
sis, damage to the vasculature, leading to the ischemia, 
and activation of nonspecific inflamation. Clinical trial of 
Photofrin-mediated intraperitoneal PDT (i. p. PDT) for 
patients with peritoneal carcinomastosis has shown fea-
sibility of this method [5]. On the other hand, stimulation 
of pro-angiogenic factors release following PDT results 
to increase of VEGF, the most powerful factor of neoan-
giogenesis that leads to restore of the microvasculature 
and reperfusion of tumor. The pro-angiogenic response 
may help the malignant cells survival and further spread 
upon peritoneal surface and to attenuate therapeutic ac-
tion of PDT. On base of understanding of the pathways 
controlling cellular functions, host/cancer interactions 
and mechanisms of cancer cell survival, photodynamic 
therapy has been combined with antiangiogenic therapy 
and demonstrated improved antitumor effect for prostate 
and pancreatic cancer in experimental studies [6–8].
Tumor host microenvironment is known to influence 
tumor cell gene expression, features of tumor growth, 
angiogenesis, metastases, drug delivery and sensitivity 
to therapeutic agents [9]. The microenvironment of the 
peritoneum and characteristics of the tumor contribute 
to the unique conditions for dissemination, distribution 
of photosensitizer and response to the photodynamic 
and/or antiangiogenic therapy. At the present time in 
preclinical trials of new therapeutic agents orthotopic 
models are considered to be adequate for correct evalu-
ation of their anticancer efficacy [10, 11].
A sensitive and non-invasive assessment of tumor 
respose to angiogenic therapy and PDT would allow 
evaluating the effictiveness of the treatment, to predict 
outcomes and to make recommendation on treatment 
scheme modification. Magnetic resonance imaging 
(MRI) can noninvasively provide a wealth of information 
regarding tumor morphology, metabolism and patholo-
gy, thereby allowing the assessment of the response to 
treatment by changes induced on these parameters. 
Several MRI techniques have been employed for the 
detection of response to therapy in various types of can-
cer in both clinical and preclinical models [12]. Recently, 
dynamic contrast-enhanced magnetic resonance imag-
ing has emerged as a useful technique for noninvasive 
imaging of tumor vasculature. This technique yields pa-
rameters related to tissue perfusion (T2w method) and 
permeabili ty (T1w method) [13]. Diffusion-weighted 
magnetic resonance imaging (DWI) is also a powerful 
tool for the assessment of damage induced in tumors 
by cytotoxic therapies when changes in cell vitality are 
often associated with significant changes in water dif-
fusion [12]. Preclinical work has shown that DWI is able 
to discriminate between nonperfused but viable and 
nonperfused, nonviable (necrotic) tissues [14].
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The purposes of this pilot preclinical work were to 
create adequate orthotopic model of peritoneal carci-
nomatosis in rats, to determine the early posttreatment 
morphologic changes in the intraperitoneal dissemi-
nated tumor, to assess the early tumor response after 
i.p. PDT and/or antiangiogenic therapy for peritoneal 
carcinomatosis using method of vital staining with 
Evans blue and MRI-monitoring.
MATERIAL AND METHODS
Animals and tumor model. The pilot study was 
carried out on eighteen white randomly bred rats 
obtained from the vivarium of the N.N. Alexandrov 
National Cancer Center of Belarus (Minsk, Belarus). 
The animals were kept on the usual daily diet.
M-1 sarcoma (Sa M-1), a transplantable rat tumor, was 
used in the experiments. The strain was obtained from the 
Oncological Research Centre of the Russian Academy of 
Medical Sciences and was passed by serial transplanta-
tion. Tumor inoculation for experiments was as follow. Tu-
mor nodes were isolated and homo genized, then Hank’s 
solution was added to yield 10% suspension. Inoculation 
was carried out via laparotomy performed under general 
anesthesia (droperidol 5 mg and fentanil 0,05 mg per 100 g 
of body mass). The abdomen was shaved and cleaned 
with 70% alcohol. The laparotomy was performed using a 
lower middle incision of 2 cm. The tumor cell suspension 
was injected under the capsule of the peritoneal surface 
in the left lower side of the abdomen. The experiments 
were performed 14–18 days after tumor transplantation.
All experiments were conducted in the compliance 
with regulation of international scientific ethic standart 
of the quality of planning and carrying out of animal 
investigations, specifically, according to “Methodology 
instruction for carrying out preclinical investigation of 
pharmacokinetics of pharmacologic substances and 
drug” presented in the “Guide on experimental (preclini-
cal) study of new pharmacologic substances” // Health 
Ministry of Russian Federation, State Pharmacologic 
Committee of Russian Federation, Moscow, 2000.
Intraperitoneal PDT and/or antiangiogenic thera-
py. Chlorin e6 conjugated with polyvinyl pyrrolidone (Foto-
lon) photosensitizer (RUE “Belmedpreparaty”, Minsk, Be-
larus) was injected in tail vein in standard dose 2.5 mg/kg.
Bevacizumab (Avastin) anti-vascular endothelial 
growth factor antibody (Genentech, Inc.; South San 
Francisco, CA) was injected in tail vein in dose 15 mg/kg.
Treatment was carried out in 18 days after inoculation 
when primary tumor reached diameter of 10–15 mm and 
peritoneal dissemination developed. All tumor-bearing 
animals were divided into three groups and undergone 
i. p. PDT (n = 5), Avastin treatment (n = 5) or i. p. PDT + 
Avastin treatment (n = 5). Three untreated animals were 
used as control.
Intraperitoneal PDT included Fotolon injection and 
illumination of abdominal cavity at laparotomy under 
general anesthesia (droperidol 5 mg and fentanil 
0.05 mg per 100 g of body mass). The abdomen was 
shaved and cleaned with 70% alcohol. Illumination regi-
men: power density of 0.03 W/cm2, a total light dose of 
5 J/cm2 for the bowel by one field with diameter 5 cm 
and with a boost treatment up to 100 J/cm2 from a point 
with diameter 1.5–2 cm for sites of gross disease. 
We used semiconductor diod laser “LD 680–2000” 
(670 nm, BioSpec, Moscow) with flat-cut optical fiber.
Avastin was administered intravenously both as 
single injection and synchronously with Fotolon injec-
tion in the combination with i. p. PDT.
Tumor response evaluation. For assessment of the 
early posttreatment response the post-PDT (n = 3), post-
Avastin (n = 3), post-PDT + Avastin (n = 3) and two control 
rats were undregone to investigation by the method of 
vital staining with Evans blue in 4 days after therapy. For 
this pupose 0.6% solution of the dye was i.v. injected at 
1 ml per 100 g of body mass. The animals were sacrificed 
in 2 h after injection; the tumor nodes were resected, 
fixed for 1 h in 10% formalin and frozen. Transverse tumor 
sections 1–1.5 mm in thickness were made. Necrotic 
tumor areas due to direct effect or structural-functional 
disoders of microcirculation remained unstained. Per-
centage of the necrotic unstained parts of the tumor were 
estimated using program ImageJ (NIH, Bethesda, USA).
In the remaining post-PDT (n = 2), post-Avastin 
(n = 2), post-PDT + Avastin (n = 2) and one control rat, 
tumor posttreatment changes were evaluated noninva-
sively by means of MRI and correlated with morphologic 
data. MRI scans were performed under general anes-
thesia. Baseline MRI was performed before treatment 
and consisted of coronal and transversal T2w and native 
T1w images followed by T1w images after intravenous 
injection of Gadolinium (Omniscan, GE Healthcare). 
Control MRI was carried out in 4 days after treatment 
following the same protocol. Animals were euthanized 
using chloroform immediately after MRI.
Morphological method of posttreatment changes 
evaluation. The treated and control animals were eutha-
nized using chloroform after the last MRI scans at 4 days 
post-PDT (n = 2), post-Avastin (n = 2), post-PDT + Avastin 
(n = 2). At necropsy, the tumors were removed, photo-
graphed and fixed in 10% neutral buffered formalin for over 
24 h. H&E staining of parallel sections of tumor nodes was 
done using standard protocol of histologic investigation.
RESULTS
Biological and morphologic characteristics of in-
traperitoneal sarcoma M-1 growth. Intraperitoneal 
transplantation of 0.25–0.3 ml 10% tumor cell suspension 
results in moderate percentage (85%) of tumor yields with 
latency of 8 days. Primary tumors were indicated by palpa-
tion in nine days. Intraperitoneal sarcoma M-1 developed 
peritoneal carcinomatosis without fail in 14–16 days after 
transplantation (Fig. 1). Firstly disseminates spread locore-
gionally, then seeding expanded over whole abdominal 
cavity. Ascitis was observed with advanced dissemination. 
Rats died in 20–22 days after inoculation due to wide-
spread of tumor mass in abdomen (Table 1).
Table 1. Biological characteristics of intraperitoneal sarcoma M-1 growth
Experi-
mental 
model
Inocula-
tion, %
Latency, 
days ± SD
Carcinoma-
tosis deve-
lopment, %
Period of carci-
nomatosis deve-
lopment, days
Mean life 
span, 
days ± SD
Sa M-1 85 8.6 ± 1.9 100 14–16 20.7 ± 1.9
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Fig. 1. Orthotopic model of peritoneal carcinomatosis in rats
Microscopically, tumor was characterized by nodular 
growth pattern with pseudocapsule formation and small 
central areas of necrosis, cytologically typified by round 
tumor cells with abundant eosinophilic cytoplasm, ve-
sicular nuclei and numerous mitotic figures. Capillaries 
proliferation was seen at the periphery of tumor lesions 
and was accompanied by weak inflammatory reaction.
Early post-treatment changes. Early post-treatment 
necrotic changes after intraperitoneal PDT and/or antian-
giogenic therapy were assessed using method of vital stain-
ing with Evans blue. Table 2 shows the data of necrosis area 
in 77 histotopographic sections of SM-1 after antiangio-
genic therapy, i. p. PDT, combination and untreated control. 
Table 2. Necrosis area in histotopographic sections of intraperitoneal 
SM-1 tumor of rats after treatment
Groups
Number 
of ani-
mals
Number 
of sec-
tions
Tumor 
square ± 
SD, cm2
Necrosis square ± SD
cm2 %
Avastin 3 18 1.53 ± 0.46 0.62 ± 0.44 41.47 ± 11.11*
i. p. PDT 3 21 0.83 ± 0.52 0.62 ± 0.23 69.73 ± 12.67**
i. p. PDT + Avastin 3 20 0.58 ± 0.55 0.51 ± 0.5 89.46 ± 7.21***
Control 2 18 2.1 ± 0.45 0.67 ± 0.21 32.5 ± 7.54
*i.p. PDT vs Avastin, p = 0.000; **i. p. PDT + Avastin vs i. p. PDT, p = 0.000; 
***i. p. PDT + Avastin vs Avastin, p = 0.000.
Percentage of necrosis in groups of animals un-
dergone Avastin, i. p. PDT and i. p. PDT + Avastin was 
41.47% (Fig. 2, a), 69.73% and 89.46% (Fig. 2, b) 
respectively. Spontaneous necrosis area in control 
animals spread up to 32.5% (Fig. 2, c).
MRI scan. Baseline MRI scans showed disseminated 
intraperitoneal tumors as heterogenous nodes with de-
fined margins. On follow-up MRI scans, control and trea-
ted tumors could be defined with areas of varying amount 
of necrosis clearly seen in all cases. Contrast-enhanced 
images of control (Fig. 3, a), post-PDT (Fig. 3, b) and 
post-Avastin rats demonstrated tumor nodes with central 
non-enhancing area of necrosis and viable enhancing 
tumor tissue on the periphery. In post-PDT + Avastin rats 
totally necrotic tumor nodes were revealed (Fig. 3, c).
a b с
Fig. 3. Contrast-enhanced MRI scans (a — control untreated 
tumor; b — post-PDT tumor; c — post-PDT + Avastin tumor)
Histological findings. Microscopically, the most 
extensive changes were seen in the post-PDT + Avastin 
tumor tissue, they were characterized by the areas of 
confluent necrosis accompanied by capillaries pro-
liferation at the margins and numerous eosinophils in 
the infiltrate (Fig. 4, a). The post-PDT + Avastin tumor 
necrosis was subtotal and occupied 90% of tumor tissue 
(Fig. 4, b). The PDT alone induced necrosis that was less 
prominent and extended approximately 75% of tumor tis-
sue (data are not shown). Sparse inflammatory infiltrate 
contained few eosinophils. The Avastin alone leaded to 
tumor necrosis that was seen in less than 50% of lesion 
and was associated with hardly defined inflammation 
(data are not shown). Unlike tumor necrosis caused by 
therapy, spontaneous necrosis in the control tumor was 
weak and represented less than 30% of tissue (Fig. 4, c).
DISCUSSION
A numerous studies emphasize the importance 
of using orthotopic tumor model in preclinical evalu-
ation of cancer treatment [9–11]. Created model of 
peritoneal carcinomatosis in rats using intraperitoneal 
transplantation of sarcoma M-1 cells suspension is 
considered to be reproducible and adequate for cor-
rect evaluation of anticancer treatment efficacy.
Since the abdomen is a very complicated area with lots 
of loops of bowel, it is very difficult to get a homo genous 
dose of light to all surfaces. Moreover, accumulation of 
photosensitizer in small disseminates may be isufficient 
due to undeveloped microvasculature. There are condi-
tions for suboptimal PDT (either not enough light or not 
enough photosensitizer or both), that can lead to regrowth 
a b с
Fig. 2. Histotopographic sections of SM-1 after vital staining with Evans blue (a — post-Avastin tumor; b — post-PDT + Avastin 
tumor; c — control untreated tumor)
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and further dissemination. Subcurative PDT-induced 
increase of VEGF secretion accompanied by an increase 
of metastases was proved in orthotopic model of prostate 
cancer [6]. Combination of antiangiogenic therapy with 
PDT is logical for leveling down proangiogenic effect of 
PDT and preventing of renovation of tumor vasculature and 
malignant cells survival. The combination is showing prom-
ise for enhancing the treatment outcome in solid tumors. 
We used intraperitoneal PDT with Fotolon and antiangio-
genic therapy with Avastin to determine efficacy of their 
combination for itraperitoneal disseminated tumors in rats.
As indicated in Table 2, neither Avastin alone nor 
i. p. PDT alone was able to lead to the significant tumor 
necrosis. But percentage of necrosis in tumor nodes 
reached up to 90% when these two suboptimal treat-
ments were combined.
For many anticancer therapies to non-invasively 
accurately monitor and quantify early tumor response 
and to determine the effictiveness of treatment regimen 
is desirable. On contrast-enhanced T1w scans 4 days 
after PDT or Avastin alone we noted a rim of viable tumor 
around central necrotic area. This finding could be result 
of either suboptimal PDT or restoring of tumor vascu-
lature or both and creation of conditions for survival 
of tumor cells with sublethal injuries and further growth. 
Synchronous application of Avastin and photosensitizer 
injections resulted in timely realization of antiangiogenic 
effect and attenuation of proangiogenic effect of PDT.
Morphologic study confirmed that tumor response 
after combination i. p. PDT + Avastin was characteri-
zed by maximal degree of necrotic and inflammatory 
changes in tumor.
In summary, in this report we presented some prelimi-
nary results demonstrating that the combination of PDT 
and antiangiogenic therapy enhanced tumor cells death 
and had significantly higher efficacy in the treatment of 
peritoneal carcinomatosis of rats comparing with each-
method alone. Non-invasive MRI-monitoring helps to 
optimize sequence and regimen of treatment combina-
tion and to assess early posttreatment response.
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Fig. 4. a — eosinophils in the infiltrate and capillaries proliferation at periphery of tumor node; b — tumor after PDT + Avastin; c — 
control untreated tumor
